| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
BNTX Stock Overview
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.
BioNTech SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$158.59 |
| 52 Week High | US$391.57 |
| 52 Week Low | US$117.08 |
| Beta | -0.076 |
| 1 Month Change | -1.75% |
| 3 Month Change | -0.16% |
| 1 Year Change | -57.60% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 1,013.69% |
Recent News & Updates
BioNTech, Genmab expand pact to develop cancer immunotherapies
BioNTech (NASDAQ:BNTX) and Genmab (GMAB) are expanding their collaboration to develop and commercialize novel immunotherapies to treat patients with cancer. Under the new agreement, the companies will jointly develop and commercialize, subject to regulatory approval, monospecific antibodies using Genmab's HexaBody technology platform for various cancer indications. The first monospecific antibody candidate GEN1053/BNT313, is expected to enter clinical trials by the end of 2022. The companies said they will equally share the development costs and potential future profit from GEN1053/BNT313. The companies currently have two jointly developed investigational medicines: GEN1046/BNT311 is being evaluated in two phase 1/2 trials to treat advanced solid tumors, and in a phase 2 study in patients with non-small cell lung cancer. Meanwhile, GEN1042/BNT312 is being evaluated to treat metastatic or locally advanced solid tumors in a phase 1/2 study. BNTX +0.40% to $181.16, GMAB -0.39% to $35.87 premarket Aug. 5
Pfizer-BioNTech's new Omicron/ancestral strain COVID vaccine enters phase 2 trial
Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) said they began a phase 2 trial of a next-generation bivalent COVID-19 mRNA vaccine candidate BNT162b5 at a 30 µg dose level. The companies added that BNT162b5 consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant. The enhanced spike protein encoded from the mRNAs in BNT162b5 has been modified with the aim of increasing immune response which could better protect against COVID-19, the companies said in a July 27 press release. BNT162b5 will be evaluated in a U.S.-based trial enrolling ~200 people aged between 18 years and 55 years who have received one booster dose of a U.S.-authorized COVID-19 vaccine at least 90 days prior to their first study visit. The study does not include a placebo. The companies noted that this was the first of multiple vaccine candidates with an enhanced design which they plan to evaluate as part of a long-term COVID-19 vaccine strategy. Pfizer (PFE) and BioNTech's (BNTX) initial COVID-19 vaccine was BNT162b2, marketed as Comirnaty. BNTX +0.49% to 160.50 premarket July 27
Calculating The Fair Value Of BioNTech SE (NASDAQ:BNTX)
Today we will run through one way of estimating the intrinsic value of BioNTech SE ( NASDAQ:BNTX ) by taking the...
Shareholder Returns
| BNTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.1% | 1.2% | 1.3% |
| 1Y | -57.6% | -23.0% | -11.7% |
Return vs Industry: BNTX underperformed the US Biotechs industry which returned -22.1% over the past year.
Return vs Market: BNTX underperformed the US Market which returned -11.6% over the past year.
Price Volatility
| BNTX volatility | |
|---|---|
| BNTX Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 12.5% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BNTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: BNTX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 3,082 | Ugur Sahin | https://www.biontech.de |
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors.
BioNTech SE Fundamentals Summary
| BNTX fundamental statistics | |
|---|---|
| Market Cap | €37.32b |
| Earnings (TTM) | €11.75b |
| Revenue (TTM) | €21.19b |
3.2x
P/E Ratio1.8x
P/S RatioIs BNTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNTX income statement (TTM) | |
|---|---|
| Revenue | €21.19b |
| Cost of Revenue | €3.85b |
| Gross Profit | €17.34b |
| Other Expenses | €5.59b |
| Earnings | €11.75b |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 07, 2022
| Earnings per share (EPS) | 48.34 |
| Gross Margin | 81.82% |
| Net Profit Margin | 55.44% |
| Debt/Equity Ratio | 0.008% |
How did BNTX perform over the long term?
See historical performance and comparison